Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 9/20 | 0.67 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.67 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.67 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.67 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.67 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.67 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.63 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.63 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.63 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.63 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.63 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5604340 | 1.00 | HDAC2 (0.67) | HDAC2HDAC8HDAC3HDAC1HDAC6 | |
| SCHEMBL1319842 | 0.89 | HDAC3 (0.73) | HDAC2HDAC8HDAC3HDAC1HDAC6 | |
| SCHEMBL1319844 | 0.89 | HDAC3 (0.73) | HDAC2HDAC8HDAC3HDAC1HDAC6 | |
| SCHEMBL6608062 | 0.86 | LMNA (0.56) | HDAC2HDAC8HDAC3HDAC1HDAC6 | |
| SCHEMBL6608068 | 0.86 | LMNA (0.56) | HDAC2HDAC8HDAC3HDAC1HDAC6 | |
| SCHEMBL14244525 | 0.83 | HDAC2 (0.67) | HDAC2HDAC8HDAC3HDAC1HDAC6 | |
| SCHEMBL14244759 | 0.83 | HDAC2 (0.89) | HDAC2HDAC8HDAC3HDAC1HDAC6 | |
| SCHEMBL12425729 | 0.83 | HDAC2 (0.89) | HDAC2HDAC8HDAC3HDAC1HDAC6 | |
| SCHEMBL12425744 | 0.83 | HDAC2 (0.67) | HDAC2HDAC8HDAC3HDAC1HDAC6 | |
| SCHEMBL2744670 | 0.82 | F3 (0.64) | CYP1A2LMNAMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9260382-B2 | Methods of reducing virulence in bacteria | UWM RESEARCH FOUNDATION (US) | 2016-02-16 | — | — | US | disclosed |
| US-20120322769-A1 | METHODS OF REDUCING VIRULENCE IN BACTERIA | DUKE UNIVERSITY (US) | 2012-12-20 | — | — | US | disclosed |
| EP-0946478-B1 | PROCESS FOR THE SOLID PHASE SYNTHESIS OF ALDEHYDES, KETONES AND HYDROXAMIC ACID COMPOUNDS | AVENTIS PHARMA INC (US) | 2007-02-14 | — | — | EP | disclosed |
| EP-1688406-A2 | Polymeric resin compounds and their preparation | Aventis Pharmaceuticals Products Inc. (US) | 2006-08-09 | — | — | EP | disclosed |
| EP-1674484-A2 | Process for the solid phase synthesis of aldehydes, ketones, oximes, amines and hydroxamic acid componds | Aventis Pharmaceuticals Products Inc. (US) | 2006-06-28 | — | — | EP | disclosed |
| EP-0946478-A4 | PROCESS FOR THE SOLID PHASE SYNTHESIS OF ALDEHYDES, KETONES, OXIMES, AMINES AND HYDROXAMIC ACID COMPOUNDS | AVENTIS PHARM PROD INC (US) | 2004-09-08 | — | — | EP | disclosed |
| US-6710208-B2 | REACTING AN N-ALKYLATED POLYMERIC HYDROXAMIC ACID RESIN WITH AN ORGANOMETALLIC REAGENT TO LIBERATE THE KETONE | AVENTIS PHARMACEUTICALS INC. | 2004-03-23 | — | — | US | disclosed |
| EP-1359136-A2 | Polymeric resin compounds and their preparation | Aventis Pharmaceuticals Products Inc. (US) | 2003-11-05 | — | — | EP | disclosed |
| US-20020183558-A1 | Process for the solid phase synthesis of aldehyde, ketone, oxime, amine, hydroxamic acid and alpha, beta-unsaturated carboxylic acid and aldehyde compounds | AVENTIS PHARMACEUTICALS INC. | 2002-12-05 | — | — | US | disclosed |
| EP-1089958-A4 | PROCESS FOR THE SOLID PHASE SYNTHESIS OF ALDEHYDE, KETONE, OXIME, AMINE, HYDROXAMIC ACID AND ALPHA,BETA-UNSATURATED CARBOXYLIC ACID AND ALDEHYDE COMPOUNDS | AVENTIS PHARM PROD INC (US) | 2002-10-09 | — | — | EP | disclosed |
| US-6392010-B1 | FLUOROPHENYL HYDROXYLAMINE RESIN | AVENTIS PHARMACEUTICALS INC. | 2002-05-21 | — | — | US | disclosed |
| EP-1089958-A2 | PROCESS FOR THE SOLID PHASE SYNTHESIS OF ALDEHYDE, KETONE, OXIME, AMINE, HYDROXAMIC ACID AND ALPHA,BETA-UNSATURATED CARBOXYLIC ACID AND ALDEHYDE COMPOUNDS | Aventis Pharmaceuticals Products Inc. (US) | 2001-04-11 | — | — | EP | disclosed |
| US-6133409-A | REACTING A SOLID SUPPORT-BOUND N-ALKYLATED HYDROXAMIC ACID WITH A CARBON-NITROGEN CLEAVING ORGANOMETALLIC COMPUND TO LIBERATE THE PRODUCT KETONE | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-10-17 | — | — | US | disclosed |
| WO-1999067192-A2 | PROCESS FOR THE SOLID PHASE SYNTHESIS OF ALDEHYDE, KETONE, OXIME, AMINE, HYDROXAMIC ACID AND α,β-UNSATURATED CARBOXYLIC ACID AND ALDEHYDE COMPOUNDS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-12-29 | — | — | WO | disclosed |
| EP-0946478-A1 | PROCESS FOR THE SOLID PHASE SYNTHESIS OF ALDEHYDES, KETONES, OXIMES, AMINES AND HYDROXAMIC ACID COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998029376-A1 | PROCESS FOR THE SOLID PHASE SYNTHESIS OF ALDEHYDES, KETONES, OXIMES, AMINES AND HYDROXAMIC ACID COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-07-09 | — | — | WO | disclosed |
| US-4820828-A | BRONCHODILATOR AGENTS, ENZYME INHIBITORS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1989-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322769-A1 | METHODS OF REDUCING VIRULENCE IN BACTERIA | PGLS, RRS1, MRPL21 | HDAC2 4243/4885HDAC8 3068/4885HDAC3 2208/4885 |
| US-20020183558-A1 | Process for the solid phase synthesis of aldehyde, ketone, oxime, amine, hydroxamic acid and alpha, beta-unsaturated carboxylic acid and aldehyde compounds | OGDH, OXGR1, ALDH7A1 | HDAC2 520/4885HDAC8 283/4885HDAC3 1019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.